54gene
A genomics pioneer that built one of Africa’s largest DNA biobanks, then collapsed under the weight of biotech economics and governance conflict.
African DNA is still under represented in global medical research. That gap weakens how well drugs, vaccines, and diagnostics work for African populations.
54gene set out to close it by building a trusted biobank and a research pipeline linking African hospitals to global scientists and pharma partners.
The company grew fast during the COVID era, when its labs earned strong testing revenue. When demand dropped, the cost base stayed high and the venture story unraveled.
The result is a landmark scientific asset, now locked in a court battle about ownership and ethics.
Key Numbers
Figures reflect public reporting through 2025.
Company
54gene was a Nigerian genomics company with research links in the United States. It built an African DNA biobank, ran genomic studies with clinical partners, and operated molecular diagnostics labs.
Leadership
How It Worked
The core asset was a biobank linked to clinical and phenotypic data. Samples were collected through hospital partners, sequenced locally, and curated into datasets for research and pharma use.
What 54gene Controlled
Growth
From 2019 to 2021, rapid funding and COVID testing revenues powered scaling. The flagship effort was the Nigerian 100,000 Genomes Project, one of the largest genomic studies on the continent.
- Flagship study. Nigeria 100,000 Genomes program launched with a public private consortium.
- Local capacity. Built sequencing infrastructure in Nigeria to keep value and skills onshore.
- Commercial pull. Pharma partners sought African datasets for global drug pipelines.
Turning Point
Post pandemic, diagnostics revenue fell and the company could not sustain the burn required for biobanking and sequencing. Two layoff rounds and a valuation reset followed in 2022.
Funding
54gene raised about $45M from global life science and Africa focused investors. After 2021, follow on funding tightened and governance tensions rose.
Landscape
Private genomics plays in Africa remain few. 54gene competed mainly with public genomics consortia, local diagnostic labs, and global sequencing firms.
| Player type | Examples | Strength | 54gene edge |
|---|---|---|---|
| Public programs | H3Africa, national institutes | Grant funding and academic depth | Faster commercial execution |
| Local labs | Hospital diagnostics units | Stable clinical demand | Deep genomics focus |
| Global firms | Large biobanks and sequencing majors | Scale and lower unit cost | Unique African datasets |
Lessons
What builders can learn from 54gene.
- Science is not enough. Big research assets need predictable revenue.
- Biotech burn is brutal. Sequencing and biobanking demand long runway and patient capital.
- Data governance is central. Consent, ownership, and national interest can define the end game.
- Board alignment matters. When trust breaks, collapse can outlive the company.
Funding rounds and valuation, public reporting 2019 to 2025.
Nigerian 100,000 Genomes program, consortium reporting 2022.
Court injunction on asset sale, Federal High Court coverage 2025.